ImmunityBio (IBRX) said Thursday that US Urology Partners has begun administering its recombinant Bacillus Calmette-Guerin, or rBCG, in the US as part of an effort to address a shortage of Tice BCG.
The company said the shortage of Tice BCG is a "significant impediment" to treating bladder cancer.
ImmunityBio said the US Food and Drug Administration recently authorized ImmunityBio's Expanded Access Program for rBCG, and 60 urology centers are preparing to launch the treatment.
The company said it is working with the Serum Institute of India to produce rBCG.
Price: 2.84, Change: -0.03, Percent Change: -1.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.